INNOVENT BIOLGCS UNSP/ADR - IVBIY STOCK NEWS

Welcome to our dedicated page for INNOVENT BIOLGCS UNSP/ADR news (Ticker: IVBIY), a resource for investors and traders seeking the latest updates and insights on INNOVENT BIOLGCS UNSP/ADR stock.

Innovent Biologics, Inc. (IVBIY) is a renowned biopharmaceutical company specializing in the development, manufacturing, and commercialization of high-quality medicines for various diseases, including oncology, cardiovascular, metabolic, autoimmune, and ophthalmology. The company's recent achievements include the publication of results from the Phase 2 TRUST-I study evaluating taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor, and the development of innovative therapies targeting CLDN18.2/CD3 and PD-1/IL-2 pathways.

Innovent Biologics has established itself as a leader in the biopharmaceutical industry, with a strong focus on empowering patients worldwide with affordable, effective treatments. With a diverse portfolio of products and ongoing clinical trials, the company continues to drive innovation and advance the field of biopharmaceuticals.

10/29/2023 08:00 PM

News

Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

Rhea-AI Summary

Innovent Biologics announces positive results from a Phase 2 clinical study of mazdutide 9 mg in Chinese subjects with obesity. Mazdutide demonstrated significant weight loss efficacy, improved cardiometabolic indicators, and a 73.3% reduction in liver fat content. The study also showed favorable safety and tolerability. Phase 3 study expected to begin by the end of 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/08/2023 08:00 PM

News

Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration

Rhea-AI Summary

Innovent Biologics announces successful dosing of first patient in Phase 3 clinical study for neovascular age-related macular degeneration (nAMD) treatment

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/28/2023 08:00 PM

News

Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

Rhea-AI Summary

Innovent Biologics and IASO Bio announce updated long-term follow-up data on BMCA CAR-T therapy for multiple myeloma

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/23/2023 07:14 AM

News

Innovent Announces 2023 Interim Results and Business Updates

Rhea-AI Summary

Innovent Biologics announces 2023 interim results and major company updates

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/16/2023 08:00 PM

News

Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia

Rhea-AI Summary

Innovent Biologics, Inc. announces that China's National Medical Products Administration has approved SINTBILO®, a PCSK9 inhibitor, for the treatment of hypercholesterolemia and mixed dyslipidemia. This is Innovent's first drug in the cardiovascular field and its tenth product in its commercial portfolio. The approval is based on three Phase 3 clinical trials, and SINTBILO® has shown significant and sustained LDL-C reduction. The approved dosing regimens provide more individualized choices for patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/07/2023 10:56 PM

News

Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer

Rhea-AI Summary

Innovent Biologics, Inc. announced that the preclinical results of IBI363 were published in Nature Cancer. The results showed that α-biased IL-2, a component of IBI363, demonstrated superior anti-tumor efficacy and lower toxicity compared to 'not-α' IL-2. IBI363, a PD-1/IL-2 bispecific antibody fusion protein, is currently in Phase 1 studies to evaluate its safety and preliminary antitumor efficacy.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

07/02/2023 08:00 PM

News

Innovent and IASO Bio Announce the NMPA Approval of FUCASO®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/25/2023 08:00 PM

News

Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/05/2023 08:00 PM

News

Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/05/2023 08:00 PM

News

Innovent and IASO Bio Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of INNOVENT BIOLGCS UNSP/ADR (IVBIY)?

The current stock price of INNOVENT BIOLGCS UNSP/ADR (IVBIY) is $19.15 as of November 21, 2024.

What is the market cap of INNOVENT BIOLGCS UNSP/ADR (IVBIY)?

The market cap of INNOVENT BIOLGCS UNSP/ADR (IVBIY) is approximately 7.8B.

What is Innovent Biologics, Inc. known for?

Innovent Biologics, Inc. is renowned for its development, manufacturing, and commercialization of high-quality medicines for various diseases, including oncology, cardiovascular, metabolic, autoimmune, and ophthalmology.

What are some recent achievements of Innovent Biologics?

Recent achievements of Innovent Biologics include the publication of results from the Phase 2 TRUST-I study evaluating taletrectinib and the development of innovative therapies targeting CLDN18.2/CD3 and PD-1/IL-2 pathways.

How does Innovent Biologics empower patients worldwide?

Innovent Biologics aims to provide affordable, high-quality biopharmaceuticals to patients worldwide, ensuring access to effective treatments for various diseases.